Momelotinib Effectiveness in Myelofibrosis

Gruppo Italiano Malattie EMatologiche dell'Adulto

Status: Not yet enrolling

Conditions: Myelofibrosis (MF)

Study type: Observational

Funder types: Other

Identifiers

NCT07249606

MPN0325

Details and patient eligibility

About

Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.

Full description

This is a multicenter prospective and retrospective observational clinical study in adult patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) being treated with momelotinib in a real-world setting. The aim of the study is to evaluate the efficacy of momelotinib in terms of splenic response. All patients are managed according to the clinical practice of the participating Center.

Enrollment: 93 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients aged 18 years or older.
2. Patients diagnosed with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis start treatment with MMB according to clinical practice from AIFA authorization.
3. Patients with palpable splenomegaly at baseline of momelotinib treatment.
4. Informed consent signed, if applicable.

Exclusion criteria

1. Diagnosis of MPN, unclassifiable, myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.
2. Accelerated/blast phase of MF.
3. Patients with platelets <20 x10(9)/L at baseline of MMB treatment.
4. Patients JAK inhibitors-exposed for other diseases apart from MF.

Trial design

93 participants in 1 patient group

MF patients treated with momelotinib

Description:

Patients diagnosed with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis treated with momelotinib according to clinical practice from AIFA authorization.